Search
macitentan (Opsumit)
Indications:
- pulmonary arterial hypertension (FDA-approved Oct 2013)
- may be of benefit in portopulmonary hypertension [2]
Contraindications:
- pregnancy category X*
* female patients can receive the drug only through the Opsumit Risk Evaluation and Mitigation Strategy (REMS) Program
Dosage:
- 10 mg PO QD [2]
Adverse effects:
- anemia
- nasopharyngitis
- bronchitis
- headache
- flu-like symptoms or influenza
- urinary tract infection
Mechanism of action:
- dual endothelin receptor antagonist
Interactions
drug adverse effects of antihypertensive agents
General
endothelin receptor antagonist
pulmonary agent
References
- FDA News Release: Oct. 18, 2013
FDA approves Opsumit to treat pulmonary arterial hypertension
- Ingram I
Opsumit Shows Promise in Portopulmonary Hypertension.
Positive results in first randomized trial in the disease.
MedPage Today. September 20, 2018
https://www.medpagetoday.com/meetingcoverage/ers/75206
- Sitbon O, et al
Efficacy and safety of macitentan in portopulmonary hypertension:
The PORTICO trial.
European Respiratory Society (ERS) 2018; Abstract OA267.
- Actelion. MACITENTAN (Manufacturer's Information Page)
http://www1.actelion.com/sites/en/scientists/development-pipeline/phase-3/macitentan.page
Component-of
macitentan/tadalafil (Opsynvi)